Advanced Inhalation Therapies (AIT) Ltd.
We are an emerging biopharmaceutical company that is developing a single proprietary 160 parts per million (ppm) nitric oxide (NO) formulation and delivery system to treat various respiratory infections for which current treatments have limited effectiveness. Our novel system is designed to safely deliver a high dosage of NO to the lungs, that, for the first time, has the potential to eliminate microbial infections including bacteria, fungi and viruses. This is in contrast to the current U.S. Food and Drug Administration (FDA) approved 20 ppm NO vasodilation treatment which is ineffective in treating microbial infections. NO is produced naturally by the body as an effective innate immunity mechanism. In order to combat severe infections, however, as demonstrated in clinical trials, higher concentrations of an NO formulation are required. To date no NO formulation and delivery system is approved by the FDA to deliver a high antimicrobial dosage to the lungs.
|Address||2 Derech Meir Weisgal, Rehovot, 7632605 Israel|
|View Prospectus:||Advanced Inhalation Therapies (AIT) Ltd.|
|Revenues||$0.0 mil (last 12 months)|
|Net Income||$-3.4 mil (last 12 months)|
|Price range||$15.00 - $15.00|
|Est. $ Volume||$5.0 mil|
|Manager / Joint Managers||Joseph Gunnar & Co.|
|Expected To Trade:||3/4/2016|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|